Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator, which is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system that provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
IPO Year: 1992
Exchange: NASDAQ
Website: misonix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2021 | Buy → Neutral | BTIG | |
| 7/30/2021 | $23.00 → $28.00 | Buy → Hold | Canaccord Genuity |
RW - MISONIX INC (0000880432) (Filer)
15-12B - MISONIX INC (0000880432) (Filer)
8-K - MISONIX INC (0000880432) (Filer)
S-8 POS - MISONIX INC (0000880432) (Filer)
S-8 POS - MISONIX INC (0000880432) (Filer)
S-8 POS - MISONIX INC (0000880432) (Filer)
S-8 POS - MISONIX INC (0000880432) (Filer)
S-8 POS - MISONIX INC (0000880432) (Filer)
S-8 POS - MISONIX INC (0000880432) (Filer)
S-8 POS - MISONIX INC (0000880432) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
4 - MISONIX INC (0000880432) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BTIG downgraded Misonix from Buy to Neutral
Canaccord Genuity downgraded Misonix from Buy to Hold and set a new price target of $28.00 from $23.00 previously
Fastest customizable press release news feed in the world
DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021, by and among Bioventus, Misonix and other parties thereto, pursuant to which Misonix will be acquired
DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the "Election Deadline") for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus ("Merger Sub I"), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus ("Me
FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below: Three Months Ended Years Ended June 30, June 30, 2021 2020 2021 2020 Revenue$19,685,141 $13,713,231 $74,024,073 $62,483,651 Gross profit$14,075,377 $9,432,383 $52,636,255 $43,709,483 Gross profit percentage 71.5% 68.8% 71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91
Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower ExtremityEnhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical OutcomesDeepens Restorative Therapies Vertical by Adding Regenerative Medicine Wound ProductsBioventus and Misonix Management to Host Joint Conference Call Today at 4:30 p.m. Eastern Time DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine
FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes today announced preliminary unaudited fiscal 2021 fourth quarter and full year revenue results for the three- and twelve-month periods ended June 30, 2021. In a separate statement issued together with Bioventus, Inc. (NASDAQ:BVS) ("Bioventus"), Misonix announced that it had entered into a definitive merger agreement pursuant to which it would, subject to the terms of the Merger Agreement ("Merger Agreement"), combine with Bioventus, a global leader in in
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Quarter Net Sales: Net Sales of $108 million to $110 million represents 86.2% to 89.7% year-over-year growth and comprises: Net sales from legacy Bioventus Inc. of $96.5 million to $98.0 million, representing organic year-over-year revenue growth* of 66.4% to 69.0%, andNet sales from the acquisition of Bioness Inc. of $11.5 million to $12.0 million. Updated Full-Year 2021 Net Sales Guidance: For the twelve
FARMINGDALE, N.Y., May 14, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced its Board of Directors has appointed Patrick J. Beyer as an independent member of the Board. Mr. Beyer joined the Board on May 12, 2021. "Pat is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout his career in the healthcare industry," stated Stavros Vizirgianakis, Chief Executive Officer of Misonix. "Pat has been an integral member of ConMed's executive team and his leadership expert
FARMINGDALE, N.Y., May 10, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Chief Executive Officer, Stavros Vizirgianakis, along with Chief Financial Officer, Joe Dwyer, will be participating in the following upcoming virtual investor conferences in May and June: Canaccord Genuity Virtual Musculoskeletal ConferenceDate: Thursday, May 20, 2021Virtual Presentation: 2:30 p.m. ET UBS Global Healthcare ConferenceDate: Tuesday, May 25, 2021Virtual Presentation: 5:00 p.m. ETA live webcast of the UBS Global Healthcare Conference fireside cha
FARMINGDALE, N.Y., May 06, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financial results for the fiscal 2021 third quarter ended March 31, 2021 as summarized below: Three Months Ended Nine Months Ended March 31, March 31, 2021 2020 2021 2020 Revenue$18,347,180 $17,902,512 $54,338,932 $48,770,419 Gross profit$12,944,426 $12,590,947 $38,560,879 $34,277,098 Gross profit percentage 70.6% 70.3% 71.0% 70.3%Pretax loss$(3,756,804) $(6,043,477) $(10,000,053) $(13,420,961)Income tax benefit$- $(455,00
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Misonix, Inc. (NASDAQ:MSON) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/event/presentation/77599To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile.About Investor NetworkInvestor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional a
Live Leadership Updates
FARMINGDALE, N.Y., May 14, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced its Board of Directors has appointed Patrick J. Beyer as an independent member of the Board. Mr. Beyer joined the Board on May 12, 2021. "Pat is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout his career in the healthcare industry," stated Stavros Vizirgianakis, Chief Executive Officer of Misonix. "Pat has been an integral member of ConMed's executive team and his leadership expert
Live finance-specific insights
FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below: Three Months Ended Years Ended June 30, June 30, 2021 2020 2021 2020 Revenue$19,685,141 $13,713,231 $74,024,073 $62,483,651 Gross profit$14,075,377 $9,432,383 $52,636,255 $43,709,483 Gross profit percentage 71.5% 68.8% 71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91
Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower ExtremityEnhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical OutcomesDeepens Restorative Therapies Vertical by Adding Regenerative Medicine Wound ProductsBioventus and Misonix Management to Host Joint Conference Call Today at 4:30 p.m. Eastern Time DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Quarter Net Sales: Net Sales of $108 million to $110 million represents 86.2% to 89.7% year-over-year growth and comprises: Net sales from legacy Bioventus Inc. of $96.5 million to $98.0 million, representing organic year-over-year revenue growth* of 66.4% to 69.0%, andNet sales from the acquisition of Bioness Inc. of $11.5 million to $12.0 million. Updated Full-Year 2021 Net Sales Guidance: For the twelve
This live feed shows all institutional transactions in real time.
SC 13G/A - MISONIX INC (0000880432) (Subject)
SC 13G/A - MISONIX INC (0000880432) (Subject)